Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed (by imaging or tissue sample) with a primary liver or bile duct cancer (such as hepatocellular carcinoma, cholangiocarcinoma, or a combined type) that occurred either without a known underlying chronic liver disease, or alongside a liver disease with no clear identified cause
- You have had surgery to remove the tumour or have received a liver transplant as a curative treatment
- You have signs of a chronic cholestatic liver condition (a condition where bile does not flow properly), shown by either: liver enzyme levels (GGT and/or alkaline phosphatase) being at least 1.5 times higher than normal on two or more tests taken at least 6 months apart, OR a history of persistent itching combined with raised bile acid levels for 6 months or more
- You are willing and able to provide written consent to take part in the trial
Who may not be able to join:
- You have another known cause of chronic liver disease that could explain your symptoms, including conditions such as primary biliary cholangitis, primary sclerosing cholangitis, IgG4-related bile duct disease, bile duct blockage, active hepatitis B, C, or E infection, heavy alcohol use, hereditary iron overload (haemochromatosis), Wilson's disease, or alpha-1 antitrypsin deficiency
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Giovanni Vitale, MD, IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phone: 051.214.3702
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Prevalence of Pathogenic and Variant Mutations in PFIC Genes in HBCs and CCLDs Patients
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.